<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01029704</url>
  </required_header>
  <id_info>
    <org_study_id>THR-1442-C-402</org_study_id>
    <nct_id>NCT01029704</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase II, Four-week, Multi-center, Double-blind, Placebo-controlled Parallel Group Study to Evaluate the Safety and Efficacy of EGT0001442 in Subjects With Type 2 Diabetes Mellitus With an Ascending Dose Safety and Pharmacokinetic Evaluation Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theracos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theracos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the effect of EGT0001442 on fasting plasma glucose&#xD;
      after 28 days of treatment in subjects with type 2 diabetes.&#xD;
&#xD;
      The study also assessed the pharmacokinetics, safety and tolerability of EGT0001442, the&#xD;
      effect on weight and HbA1c as well as the effect EGT0001442 has on the amount of glucose&#xD;
      produced in the body by the urine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a phase 2 study to evaluate the efficacy of&#xD;
&#xD;
      EGT0001442. The study included two segments:&#xD;
&#xD;
      Segment 1 was a single center, open labeled, ascending dose study in 4 groups of 5 diabetic&#xD;
      subjects per group who received 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily&#xD;
      for 28 days. The subjects were in clinic for the first 3 days for safety and PK evaluation.&#xD;
&#xD;
      Segment 2 was a multi-center, double-blind, placebo-controlled parallel group study. One&#xD;
      hundred and thirty one subjects in 5 parallel groups of approximately 25 diabetic subjects&#xD;
      per group were randomly assigned to receive oral EGT0001442 at 5, 10, 20, or 50 mg/day or&#xD;
      placebo once daily for 28 days in an outpatient setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Fasting Plasma Glucose (FPG) From Baseline at Week 4 for Segment 2 of the Study</measure>
    <time_frame>Baseline; Day -2 and Day 1. End of Treatment: Day 27 and Day 29</time_frame>
    <description>Fasting glucose levels were measured at four time points; At day -2, day 1, day 27 and day 29 (24-h after the last dose). Baseline is defined as the mean of FPG values on day -2 and day 1. End of treatment is defined as the mean of FPG values on day 27 and day 29. Changes in the FPG during the study period was calculated by subtracting the Baseline FPG from End of Treatment FPG.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of EGT0001442 (Cmax) at 4 Dose Levels at Week 4</measure>
    <time_frame>Pre-dose to 48 h post-dose</time_frame>
    <description>Blood samples were collected during Segment 1 at pre-dose and at 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12 and 24 h (day 2), and 48 h (day 3) post dose for the determination of EGT0001442. Plasma concentrations of EGT0001442 were measured using a validated HPLC/MS-MS method and PK parameters were calculated by standard noncompartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of EGT0001442 (AUC 0-t and 0-24) at 4 Dose Levels at Week 4</measure>
    <time_frame>Pre-dose to 48 h post-dose</time_frame>
    <description>Blood samples were collected during Segment 1 at pre-dose and at 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12 and 24 h (day 2), and 48 h (day 3) post dose for the determination of EGT0001442. Plasma concentrations of EGT0001442 were measured using a validated HPLC/MS-MS method and PK parameters were calculated by standard noncompartmental methods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Body Weight From Baseline at Week 4</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Changes in the body weight during the study period was calculated by subtracting body weight on day 1 from body weight at the end of treatment on day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hemoglobin A1c (HbA1c) From Baseline at Week 4</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>HbA1c levels were measured at two time points; on day 1 and day 29 (end of treatment). Changes in the HbA1c level during the study period was calculated by subtracting HbA1c level on day 1 from HbA1c level at the end of treatment (day 29)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary Glucose Excretion From Baseline to Day 1 and Day 28</measure>
    <time_frame>Baseline, Day 1 and Day 28</time_frame>
    <description>Urinary glucose levels were measured at three time points; on Day 0 (baseline), Day 1 and Day 28 (end of treatment). Changes in the urinary glucose level during the study period was calculated by reducing the baseline urinary glucose level (Day 1) from urinary glucose level at end of treatment (Day 28) (i.e urinary glucose level on Day 28 minus urinary glucose level on Day 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FPG Following Cessation of Treatment</measure>
    <time_frame>Days 27/29 to Days 41/43</time_frame>
    <description>The mean change in FPG following cessation of treatment was obtained by calculating the difference between FPG values obtained on End of treatment (average of FPG values on days 27 and 29) and on Post Treatment (average of FPG values on days 41 and 43).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>EGT0001442</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGT0001442</intervention_name>
    <description>Segment 1 is a single center, open labeled, ascending dose study in diabetic subjects who will receive 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days.&#xD;
Segment 2 is a multi-center, double-blind, placebo-controlled parallel group study. Diabetic subjects will be randomly assigned to receive oral EGT0001442 at 5, 10, 20, or 50 mg/day for 28 days.</description>
    <arm_group_label>EGT0001442</arm_group_label>
    <other_name>Human SGLT2 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules to match EGT0001442</intervention_name>
    <description>Segment 1: Not applicable.&#xD;
Segment 2: Diabetic subjects will be randomly assigned to receive oral placebo once daily for 28 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Human SGLT2 inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female between the ages of 18 and 70 years diagnosed with type 2 diabetes.&#xD;
&#xD;
          -  Body mass index (BMI) between 18 kg/m2 and 37 kg/m2 (inclusive).&#xD;
&#xD;
          -  HbA1c levels between 6.5 and 9.5 (inclusive) where the upper limit of normal for the&#xD;
             HbA1c assay is 6.4% or HbA1c levels between 6.2 and 9.5% (inclusive) where the upper&#xD;
             limit of normal for the HbA1c assay is 6.1%.&#xD;
&#xD;
          -  Fasting plasma glucose levels between 126 and 270 mg/dL (7 - 15 mmol/L, inclusive)&#xD;
             while on diabetic medications.&#xD;
&#xD;
          -  Treatment na√Øve subjects with HbA1c between 6.5 and 9.5 and fasting plasma glucose&#xD;
             between 126 and 270 mg/dL (7 - 15 mmol/L).&#xD;
&#xD;
          -  If taking drugs for diabetes, must be medically able and willing to discontinue&#xD;
             diabetic medications for the duration of the study.&#xD;
&#xD;
          -  Female subjects must be surgically sterilized or postmenopausal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes or diabetes treated with insulin injection.&#xD;
&#xD;
          -  Insulin therapy or oral antidiabetic medication other than metformin, sitagliptin,&#xD;
             saxagliptin, a sulfonylurea or combination of these.&#xD;
&#xD;
          -  Sitting blood pressure above 150/95 mmHg on two evaluations at least 10 minutes apart&#xD;
             at screening.&#xD;
&#xD;
          -  Positive results on screen for drugs of abuse.&#xD;
&#xD;
          -  Previous treatment with an investigational drug within 30 days or 7 half-lives,&#xD;
             whichever is longer.&#xD;
&#xD;
          -  Previous treatment with EGT0001474 or EGT0001442.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mason W Freeman, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site #10</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #04</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #12</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #07</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #08</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #06</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #11</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #01</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #15</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #03</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #13</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #02</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 9, 2009</study_first_submitted>
  <study_first_submitted_qc>December 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2009</study_first_posted>
  <results_first_submitted>June 21, 2011</results_first_submitted>
  <results_first_submitted_qc>June 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 20, 2011</results_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus Type 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium-Glucose Transporter 2 Inhibitors</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 17, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT01029704/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Segment 1 (Dose Escalation): EGT0001442 5mg</title>
          <description>Received 5mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="P2">
          <title>Segment 1 (Dose Escalation): EGT0001442 10mg</title>
          <description>Received 10mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="P3">
          <title>Segment 1 (Dose Escalation): EGT0001442 20mg</title>
          <description>Received 20mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="P4">
          <title>Segment 1 (Dose Escalation): EGT0001442 50mg</title>
          <description>Received 50mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="P5">
          <title>Segment 2 (Double-blind): Placebo</title>
          <description>Received placebo once daily for 28 days</description>
        </group>
        <group group_id="P6">
          <title>Segment 2 (Double-blind): EGT0001442 5mg</title>
          <description>Received 5mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="P7">
          <title>Segment 2 (Double-blind): EGT0001442 10mg</title>
          <description>Received 10mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="P8">
          <title>Segment 2 (Double-blind): EGT0001442 20mg</title>
          <description>Received 20mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="P9">
          <title>Segment 2 (Double-blind): EGT0001442 50mg</title>
          <description>Received 50mg of EGT0001442 once daily for 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="24"/>
                <participants group_id="P7" count="23"/>
                <participants group_id="P8" count="28"/>
                <participants group_id="P9" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="20"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="22"/>
                <participants group_id="P9" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn due to major protocol violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Segment 1 (Dose Escalation): EGT0001442 5mg</title>
          <description>Received 5mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="B2">
          <title>Segment 1 (Dose Escalation): EGT0001442 10mg</title>
          <description>Received 10mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="B3">
          <title>Segment 1 (Dose Escalation): EGT0001442 20mg</title>
          <description>Received 20mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="B4">
          <title>Segment 1 (Dose Escalation): EGT0001442 50mg</title>
          <description>Received 50mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="B5">
          <title>Segment 2 (Double-blind): Placebo</title>
          <description>Received placebo once daily for 28 days</description>
        </group>
        <group group_id="B6">
          <title>Segment 2 (Double-blind): EGT0001442 5mg</title>
          <description>Received 5mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="B7">
          <title>Segment 2 (Double-blind): EGT0001442 10mg</title>
          <description>Received 10mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="B8">
          <title>Segment 2 (Double-blind): EGT0001442 20mg</title>
          <description>Received 20mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="B9">
          <title>Segment 2 (Double-blind): EGT0001442 50mg</title>
          <description>Received 50mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="28"/>
            <count group_id="B6" value="24"/>
            <count group_id="B7" value="23"/>
            <count group_id="B8" value="28"/>
            <count group_id="B9" value="26"/>
            <count group_id="B10" value="149"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Segment 1 only applies to Dose Escalation group. Segment 2 only applies to Double-blind treatment group.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Segment 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="7.9"/>
                    <measurement group_id="B2" value="49.4" spread="14.2"/>
                    <measurement group_id="B3" value="51.4" spread="11.7"/>
                    <measurement group_id="B4" value="53.2" spread="5.8"/>
                    <measurement group_id="B10" value="54.1" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segment 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="28"/>
                    <count group_id="B6" value="24"/>
                    <count group_id="B7" value="23"/>
                    <count group_id="B8" value="28"/>
                    <count group_id="B9" value="26"/>
                    <count group_id="B10" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="58.7" spread="7.3"/>
                    <measurement group_id="B6" value="57.8" spread="6.9"/>
                    <measurement group_id="B7" value="54.9" spread="9"/>
                    <measurement group_id="B8" value="59" spread="7.1"/>
                    <measurement group_id="B9" value="54.7" spread="6.7"/>
                    <measurement group_id="B10" value="57.1" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Segment 1 only applies to Dose Escalation group. Segment 2 only applies to Double-blind treatment group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Segment 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segment 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="28"/>
                    <count group_id="B6" value="24"/>
                    <count group_id="B7" value="23"/>
                    <count group_id="B8" value="28"/>
                    <count group_id="B9" value="26"/>
                    <count group_id="B10" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="18"/>
                    <measurement group_id="B10" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="16"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Segment 1 only applies to Dose Escalation group. Segment 2 only applies to Double-blind treatment group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Segment 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segment 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="28"/>
                    <count group_id="B6" value="24"/>
                    <count group_id="B7" value="23"/>
                    <count group_id="B8" value="28"/>
                    <count group_id="B9" value="26"/>
                    <count group_id="B10" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="19"/>
                    <measurement group_id="B9" value="19"/>
                    <measurement group_id="B10" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Segment 1 only applies to Dose Escalation group. Segment 2 only applies to Double-blind treatment group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Segment 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segment 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="28"/>
                    <count group_id="B6" value="24"/>
                    <count group_id="B7" value="23"/>
                    <count group_id="B8" value="28"/>
                    <count group_id="B9" value="26"/>
                    <count group_id="B10" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="22"/>
                    <measurement group_id="B9" value="24"/>
                    <measurement group_id="B10" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>Segment 1 only applies to Dose Escalation group. Segment 2 only applies to Double-blind treatment group.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Segment 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.04" spread="11.49"/>
                    <measurement group_id="B2" value="167.34" spread="11.42"/>
                    <measurement group_id="B3" value="163.74" spread="9.10"/>
                    <measurement group_id="B4" value="172.80" spread="9.00"/>
                    <measurement group_id="B10" value="168.98" spread="10.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segment 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="28"/>
                    <count group_id="B6" value="24"/>
                    <count group_id="B7" value="23"/>
                    <count group_id="B8" value="28"/>
                    <count group_id="B9" value="26"/>
                    <count group_id="B10" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="167.76" spread="11.09"/>
                    <measurement group_id="B6" value="170.15" spread="9.32"/>
                    <measurement group_id="B7" value="167.50" spread="9.83"/>
                    <measurement group_id="B8" value="166.71" spread="9.60"/>
                    <measurement group_id="B9" value="164.92" spread="10.98"/>
                    <measurement group_id="B10" value="167.36" spread="10.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>Segment 1 only applies to Dose Escalation group. Segment 2 only applies to Double-blind treatment group.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Segment 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.04" spread="14.48"/>
                    <measurement group_id="B2" value="83.72" spread="9.86"/>
                    <measurement group_id="B3" value="92.18" spread="16.65"/>
                    <measurement group_id="B4" value="87.22" spread="12.81"/>
                    <measurement group_id="B10" value="88.54" spread="13.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segment 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="28"/>
                    <count group_id="B6" value="24"/>
                    <count group_id="B7" value="23"/>
                    <count group_id="B8" value="28"/>
                    <count group_id="B9" value="26"/>
                    <count group_id="B10" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="84.34" spread="15.83"/>
                    <measurement group_id="B6" value="86.75" spread="13.53"/>
                    <measurement group_id="B7" value="81.40" spread="15.03"/>
                    <measurement group_id="B8" value="81.03" spread="12.17"/>
                    <measurement group_id="B9" value="84.18" spread="17.61"/>
                    <measurement group_id="B10" value="83.51" spread="14.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <population>Segment 1 only applies to Dose Escalation group. Segment 2 only applies to Double-blind treatment group.</population>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Segment 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.58" spread="1.85"/>
                    <measurement group_id="B2" value="30.00" spread="3.39"/>
                    <measurement group_id="B3" value="34.18" spread="3.58"/>
                    <measurement group_id="B4" value="29.14" spread="2.94"/>
                    <measurement group_id="B10" value="30.98" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segment 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="28"/>
                    <count group_id="B6" value="24"/>
                    <count group_id="B7" value="23"/>
                    <count group_id="B8" value="28"/>
                    <count group_id="B9" value="26"/>
                    <count group_id="B10" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="29.77" spread="3.03"/>
                    <measurement group_id="B6" value="29.96" spread="3.98"/>
                    <measurement group_id="B7" value="28.91" spread="4.02"/>
                    <measurement group_id="B8" value="29.10" spread="3.30"/>
                    <measurement group_id="B9" value="30.75" spread="4.47"/>
                    <measurement group_id="B10" value="29.70" spread="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Fasting Plasma Glucose (FPG) From Baseline at Week 4 for Segment 2 of the Study</title>
        <description>Fasting glucose levels were measured at four time points; At day -2, day 1, day 27 and day 29 (24-h after the last dose). Baseline is defined as the mean of FPG values on day -2 and day 1. End of treatment is defined as the mean of FPG values on day 27 and day 29. Changes in the FPG during the study period was calculated by subtracting the Baseline FPG from End of Treatment FPG.</description>
        <time_frame>Baseline; Day -2 and Day 1. End of Treatment: Day 27 and Day 29</time_frame>
        <population>Subjects participated in Segment 2 of the study were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received no drug (EGT0001442) during 28 days</description>
          </group>
          <group group_id="O2">
            <title>EGT0001442 5mg</title>
            <description>Received 5mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>EGT0001442 10mg</title>
            <description>Received 10mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>EGT0001442 20mg</title>
            <description>Received 20mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O5">
            <title>EGT0001442 50mg</title>
            <description>Received 50mg of EGT0001442 per day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Fasting Plasma Glucose (FPG) From Baseline at Week 4 for Segment 2 of the Study</title>
          <description>Fasting glucose levels were measured at four time points; At day -2, day 1, day 27 and day 29 (24-h after the last dose). Baseline is defined as the mean of FPG values on day -2 and day 1. End of treatment is defined as the mean of FPG values on day 27 and day 29. Changes in the FPG during the study period was calculated by subtracting the Baseline FPG from End of Treatment FPG.</description>
          <population>Subjects participated in Segment 2 of the study were included in the analysis.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.595" spread="7.025"/>
                    <measurement group_id="O2" value="-29.518" spread="7.767"/>
                    <measurement group_id="O3" value="-30.429" spread="8.386"/>
                    <measurement group_id="O4" value="-32.586" spread="7.305"/>
                    <measurement group_id="O5" value="-44.605" spread="7.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0989</p_value>
            <p_value_desc>P-values are from two-sided test at 5% level</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis is based on ANCOVA with change from baseline as dependent variable and treatment as fixed effect and baseline and center as covariate.</method_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>-16.923</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.076</ci_lower_limit>
            <ci_upper_limit>3.230</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0964</p_value>
            <p_value_desc>P-values are from two-sided test at 5% level</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis is based on ANCOVA with change from baseline as dependent variable and treatment as fixed effect and baseline and center as covariate.</method_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>-17.834</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.909</ci_lower_limit>
            <ci_upper_limit>3.242</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0465</p_value>
            <p_value_desc>P-values are from two-sided test at 5% level</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis is based on ANCOVA with change from baseline as dependent variable and treatment as fixed effect and baseline and center as covariate.</method_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>-19.991</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.670</ci_lower_limit>
            <ci_upper_limit>-0.312</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0015</p_value>
            <p_value_desc>P-values are from two-sided test at 5% level</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis is based on ANCOVA with change from baseline as dependent variable and treatment as fixed effect and baseline and center as covariate.</method_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>-32.010</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.487</ci_lower_limit>
            <ci_upper_limit>-12.533</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of EGT0001442 (Cmax) at 4 Dose Levels at Week 4</title>
        <description>Blood samples were collected during Segment 1 at pre-dose and at 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12 and 24 h (day 2), and 48 h (day 3) post dose for the determination of EGT0001442. Plasma concentrations of EGT0001442 were measured using a validated HPLC/MS-MS method and PK parameters were calculated by standard noncompartmental methods.</description>
        <time_frame>Pre-dose to 48 h post-dose</time_frame>
        <population>20 subjects in Segment 1 of the study were included in the analysis. The PK study was not included in Segment 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Segment 1 (Dose Escalation): EGT0001442 5mg</title>
            <description>Received 5mg of EGT0001442 once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Segment 1 (Dose Escalation): EGT0001442 10mg</title>
            <description>Received 10mg of EGT0001442 once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Segment 1 (Dose Escalation): EGT0001442 20mg</title>
            <description>Received 20mg of EGT0001442 once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Segment 1 (Dose Escalation): EGT0001442 50mg</title>
            <description>Received 50mg of EGT0001442 once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of EGT0001442 (Cmax) at 4 Dose Levels at Week 4</title>
          <description>Blood samples were collected during Segment 1 at pre-dose and at 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12 and 24 h (day 2), and 48 h (day 3) post dose for the determination of EGT0001442. Plasma concentrations of EGT0001442 were measured using a validated HPLC/MS-MS method and PK parameters were calculated by standard noncompartmental methods.</description>
          <population>20 subjects in Segment 1 of the study were included in the analysis. The PK study was not included in Segment 2.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.42" spread="15.21"/>
                    <measurement group_id="O2" value="83.38" spread="30.93"/>
                    <measurement group_id="O3" value="164.20" spread="40.21"/>
                    <measurement group_id="O4" value="541.20" spread="192.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Body Weight From Baseline at Week 4</title>
        <description>Changes in the body weight during the study period was calculated by subtracting body weight on day 1 from body weight at the end of treatment on day 29.</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>Subjects participated in Segment 2 of the study were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received no drug (EGT0001442) during 28 days</description>
          </group>
          <group group_id="O2">
            <title>EGT0001442 5mg</title>
            <description>Received 5mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>EGT0001442 10mg</title>
            <description>Received 10mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>EGT0001442 20mg</title>
            <description>Received 20mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O5">
            <title>EGT0001442 50mg</title>
            <description>Received 50mg of EGT0001442 per day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Body Weight From Baseline at Week 4</title>
          <description>Changes in the body weight during the study period was calculated by subtracting body weight on day 1 from body weight at the end of treatment on day 29.</description>
          <population>Subjects participated in Segment 2 of the study were included in the analysis.</population>
          <units>Kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.258" spread="0.304"/>
                    <measurement group_id="O2" value="-1.176" spread="0.345"/>
                    <measurement group_id="O3" value="-0.779" spread="0.346"/>
                    <measurement group_id="O4" value="-1.796" spread="0.324"/>
                    <measurement group_id="O5" value="-0.914" spread="0.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0025</p_value>
            <p_value_desc>P-values are from a two-sided test.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis is based on ANCOVA with change from baseline as dependent variable and treatment as fixed effect and baseline and center as covariate.</method_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>-1.434</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.349</ci_lower_limit>
            <ci_upper_limit>-0.520</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0269</p_value>
            <p_value_desc>P-values are from a two-sided test</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis is based on ANCOVA with change from baseline as dependent variable and treatment as fixed effect and baseline and center as covariate.</method_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>-1.037</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.952</ci_lower_limit>
            <ci_upper_limit>-0.122</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>P-values are from a two-sided test</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis is based on ANCOVA with change from baseline as dependent variable and treatment as fixed effect and baseline and center as covariate.</method_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>-2.054</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.938</ci_lower_limit>
            <ci_upper_limit>-1.170</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0090</p_value>
            <p_value_desc>P-values are from a two-sided test</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis is based on ANCOVA with change from baseline as dependent variable and treatment as fixed effect and baseline and center as covariate.</method_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>-1.172</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.044</ci_lower_limit>
            <ci_upper_limit>-0.301</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Hemoglobin A1c (HbA1c) From Baseline at Week 4</title>
        <description>HbA1c levels were measured at two time points; on day 1 and day 29 (end of treatment). Changes in the HbA1c level during the study period was calculated by subtracting HbA1c level on day 1 from HbA1c level at the end of treatment (day 29)</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>Subjects participated in Segment 2 of the study were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received no drug (EGT0001442) during 28 days</description>
          </group>
          <group group_id="O2">
            <title>EGT0001442 5mg</title>
            <description>Received 5mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>EGT0001442 10mg</title>
            <description>Received 10mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>EGT0001442 20mg</title>
            <description>Received 20mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O5">
            <title>EGT0001442 50mg</title>
            <description>Received 50mg of EGT0001442 per day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Hemoglobin A1c (HbA1c) From Baseline at Week 4</title>
          <description>HbA1c levels were measured at two time points; on day 1 and day 29 (end of treatment). Changes in the HbA1c level during the study period was calculated by subtracting HbA1c level on day 1 from HbA1c level at the end of treatment (day 29)</description>
          <population>Subjects participated in Segment 2 of the study were included in the analysis.</population>
          <units>percentage of HbA1c</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.178" spread="0.107"/>
                    <measurement group_id="O2" value="-0.176" spread="0.122"/>
                    <measurement group_id="O3" value="0.022" spread="0.123"/>
                    <measurement group_id="O4" value="0.173" spread="0.115"/>
                    <measurement group_id="O5" value="-0.167" spread="0.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0281</p_value>
            <p_value_desc>P-values are from a two-sided test</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis is based on ANCOVA with change from baseline as dependent variable and treatment as fixed effect and baseline and center as covariate.</method_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.353</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.668</ci_lower_limit>
            <ci_upper_limit>-0.039</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3215</p_value>
            <p_value_desc>P-values are from a two-sided test</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis is based on ANCOVA with change from baseline as dependent variable and treatment as fixed effect and baseline and center as covariate.</method_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.155</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.464</ci_lower_limit>
            <ci_upper_limit>0.154</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9776</p_value>
            <p_value_desc>P-values are from a two-sided test</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis is based on ANCOVA with change from baseline as dependent variable and treatment as fixed effect and baseline and center as covariate.</method_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.004</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.304</ci_lower_limit>
            <ci_upper_limit>0.295</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0242</p_value>
            <p_value_desc>P-values are from a two-sided test</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis is based on ANCOVA with change from baseline as dependent variable and treatment as fixed effect and baseline and center as covariate.</method_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.344</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.642</ci_lower_limit>
            <ci_upper_limit>-0.046</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urinary Glucose Excretion From Baseline to Day 1 and Day 28</title>
        <description>Urinary glucose levels were measured at three time points; on Day 0 (baseline), Day 1 and Day 28 (end of treatment). Changes in the urinary glucose level during the study period was calculated by reducing the baseline urinary glucose level (Day 1) from urinary glucose level at end of treatment (Day 28) (i.e urinary glucose level on Day 28 minus urinary glucose level on Day 1).</description>
        <time_frame>Baseline, Day 1 and Day 28</time_frame>
        <population>Only number of subjects with data available in the specific treatment group is included</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received no drug (EGT0001442) during 28 days</description>
          </group>
          <group group_id="O2">
            <title>EGT0001442 5mg</title>
            <description>Received 5mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>EGT0001442 10mg</title>
            <description>Received 10mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>EGT0001442 20mg</title>
            <description>Received 20mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O5">
            <title>EGT0001442 50mg</title>
            <description>Received 50mg of EGT0001442 per day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Glucose Excretion From Baseline to Day 1 and Day 28</title>
          <description>Urinary glucose levels were measured at three time points; on Day 0 (baseline), Day 1 and Day 28 (end of treatment). Changes in the urinary glucose level during the study period was calculated by reducing the baseline urinary glucose level (Day 1) from urinary glucose level at end of treatment (Day 28) (i.e urinary glucose level on Day 28 minus urinary glucose level on Day 1).</description>
          <population>Only number of subjects with data available in the specific treatment group is included</population>
          <units>g/24h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in 24 h UGE from baseline to Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.55" spread="13.05"/>
                    <measurement group_id="O2" value="26.21" spread="11.08"/>
                    <measurement group_id="O3" value="24.17" spread="16.89"/>
                    <measurement group_id="O4" value="25.13" spread="12.72"/>
                    <measurement group_id="O5" value="29.61" spread="20.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in 24 h UGE from baseline to Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="14.98"/>
                    <measurement group_id="O2" value="22.57" spread="16.56"/>
                    <measurement group_id="O3" value="18.71" spread="20.46"/>
                    <measurement group_id="O4" value="21.01" spread="16.43"/>
                    <measurement group_id="O5" value="26.80" spread="19.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FPG Following Cessation of Treatment</title>
        <description>The mean change in FPG following cessation of treatment was obtained by calculating the difference between FPG values obtained on End of treatment (average of FPG values on days 27 and 29) and on Post Treatment (average of FPG values on days 41 and 43).</description>
        <time_frame>Days 27/29 to Days 41/43</time_frame>
        <population>Subjects participated in Segment 2 of the study and had fasting plasma glucose (FPG) values at the end of treatment (mean FPG value on days 27 and 29) and at post-treatment (mean FPG values on days 41 and 43) are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received no drug (EGT0001442) during 28 days</description>
          </group>
          <group group_id="O2">
            <title>EGT0001442 5mg</title>
            <description>Received 5mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>EGT0001442 10mg</title>
            <description>Received 10mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>EGT0001442 20mg</title>
            <description>Received 20mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O5">
            <title>EGT0001442 50mg</title>
            <description>Received 50mg of EGT0001442 per day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FPG Following Cessation of Treatment</title>
          <description>The mean change in FPG following cessation of treatment was obtained by calculating the difference between FPG values obtained on End of treatment (average of FPG values on days 27 and 29) and on Post Treatment (average of FPG values on days 41 and 43).</description>
          <population>Subjects participated in Segment 2 of the study and had fasting plasma glucose (FPG) values at the end of treatment (mean FPG value on days 27 and 29) and at post-treatment (mean FPG values on days 41 and 43) are included in the analysis.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.058" spread="8.256"/>
                    <measurement group_id="O2" value="17.746" spread="8.896"/>
                    <measurement group_id="O3" value="17.148" spread="10.421"/>
                    <measurement group_id="O4" value="24.437" spread="7.989"/>
                    <measurement group_id="O5" value="20.807" spread="8.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1613</p_value>
            <p_value_desc>P-values are from a two-sided test</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis is based on ANCOVA with change from baseline as dependent variable and treatment as fixed effect and baseline and center as covariate.</method_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>17.688</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.210</ci_lower_limit>
            <ci_upper_limit>42.587</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2079</p_value>
            <p_value_desc>P-values are from a two-sided test</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis is based on ANCOVA with change from baseline as dependent variable and treatment as fixed effect and baseline and center as covariate.</method_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>17.091</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.696</ci_lower_limit>
            <ci_upper_limit>43.877</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0410</p_value>
            <p_value_desc>P-values are from a two-sided test</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis is based on ANCOVA with change from baseline as dependent variable and treatment as fixed effect and baseline and center as covariate.</method_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>24.379</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.028</ci_lower_limit>
            <ci_upper_limit>47.731</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0862</p_value>
            <p_value_desc>P-values are from a two-sided test</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis is based on ANCOVA with change from baseline as dependent variable and treatment as fixed effect and baseline and center as covariate.</method_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>20.749</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.019</ci_lower_limit>
            <ci_upper_limit>44.518</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of EGT0001442 (AUC 0-t and 0-24) at 4 Dose Levels at Week 4</title>
        <description>Blood samples were collected during Segment 1 at pre-dose and at 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12 and 24 h (day 2), and 48 h (day 3) post dose for the determination of EGT0001442. Plasma concentrations of EGT0001442 were measured using a validated HPLC/MS-MS method and PK parameters were calculated by standard noncompartmental methods.</description>
        <time_frame>Pre-dose to 48 h post-dose</time_frame>
        <population>20 subjects in Segment 1 of the study were included in the analysis. The PK study was not included in Segment 2.&#xD;
AUC0-24 values for two participants in 5 mg arm were not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Segment 1 (Dose Escalation): EGT0001442 5mg</title>
            <description>Received 5mg of EGT0001442 once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Segment 1 (Dose Escalation): EGT0001442 10mg</title>
            <description>Received 10mg of EGT0001442 once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Segment 1 (Dose Escalation): EGT0001442 20mg</title>
            <description>Received 20mg of EGT0001442 once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Segment 1 (Dose Escalation): EGT0001442 50mg</title>
            <description>Received 50mg of EGT0001442 once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of EGT0001442 (AUC 0-t and 0-24) at 4 Dose Levels at Week 4</title>
          <description>Blood samples were collected during Segment 1 at pre-dose and at 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12 and 24 h (day 2), and 48 h (day 3) post dose for the determination of EGT0001442. Plasma concentrations of EGT0001442 were measured using a validated HPLC/MS-MS method and PK parameters were calculated by standard noncompartmental methods.</description>
          <population>20 subjects in Segment 1 of the study were included in the analysis. The PK study was not included in Segment 2.&#xD;
AUC0-24 values for two participants in 5 mg arm were not calculated.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-t</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334.02" spread="51.80"/>
                    <measurement group_id="O2" value="681.88" spread="74.66"/>
                    <measurement group_id="O3" value="1312.36" spread="487.28"/>
                    <measurement group_id="O4" value="3308.88" spread="785.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328.85" spread="56.07"/>
                    <measurement group_id="O2" value="548.15" spread="70.41"/>
                    <measurement group_id="O3" value="1076.39" spread="373.15"/>
                    <measurement group_id="O4" value="2755.68" spread="586.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected from Day -7 (Visit 3; Washout monitor) to Day 43 (Visit 14; Termination)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Segment 1 (Dose Escalation): EGT0001442 5mg</title>
          <description>Received 5mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="E2">
          <title>Segment 1 (Dose Escalation): EGT0001442 10mg</title>
          <description>Received 10mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="E3">
          <title>Segment 1 (Dose Escalation): EGT0001442 20mg</title>
          <description>Received 20mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="E4">
          <title>Segment 1 (Dose Escalation): EGT0001442 50mg</title>
          <description>Received 50mg of EGT0001442 once daily for 28 days</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Received no drug (EGT0001442) during 28 days</description>
        </group>
        <group group_id="E6">
          <title>EGT0001442 5mg</title>
          <description>Received 5mg of EGT0001442 per day for 28 days</description>
        </group>
        <group group_id="E7">
          <title>EGT0001442 10mg</title>
          <description>Received 10mg of EGT0001442 per day for 28 days</description>
        </group>
        <group group_id="E8">
          <title>EGT0001442 20mg</title>
          <description>Received 20mg of EGT0001442 per day for 28 days</description>
        </group>
        <group group_id="E9">
          <title>EGT0001442 50mg</title>
          <description>Received 50mg of EGT0001442 per day for 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Balanitis candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Investigator does not have the right to publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Albert Collinson</name_or_title>
      <organization>Theracos, Inc.</organization>
      <phone>(508) 630-2129</phone>
      <email>acollinson@theracos.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

